Codes of Conduct


Since 1987 APIFARMA is governed by Codes of Ethics which, as time goes by, have gone under changes as a result of the changes with national and community legislation and the ongoing need to clarify concepts and practices.


On the other hand, various versions of Code of Ethics were influenced also by the Code of Ethics of IFPMA (International Federation of Pharmaceutical Manufacturers and Associations) and EFPIA (European Federation of Pharmaceutical Industries and Associations) of which our association is a member.

This version merges in a single body the previous version of the Code and the recent EFPIA Code of Ethics approved in October 2007, integrating the aspects regarding advertising of medicinal products in compliance with Decree-Law no. 176/2006, of 30 August.

This Code of Ethics governs the relations of Patients Organizations with the Pharmaceutical Industry, referring this subject to Code of Conduct for the relations between Pharmaceutical Industry and Patients Organizations.

Emerging from the approval of the community code (Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001) and aiming at improving and make the self-regulation system more efficient, principles and standards of internal conduct, resulting from the ongoing need to make proceedings become swifter, were sanctioned in line with similar European Associations.

APIFARMA Code of Ethics does not aim at restraining the promotion of medicinal products in such a way as to hinder free competition, seeking rather to ensure that member pharmaceutical companies engage in an ethical promotion, restraining from deceitful practices and potential conflicts of interest with health care professionals, whilst complying with applicable laws and regulations for the benefit of the name and prestige of the Pharmaceutical Industry.

Therefore, the purpose of APIFARMA Code of Ethics is to enable an environment where the general public may be sure that the choices regarding their medicinal products are made based on the merit of each product and the patients’ clinical needs.

The rules sanctioned here were freely discussed and voluntarily accepted, and are binding for all APIFARMA members.